The President, CEO and founder of ImmunoScience, Inc. is Dr. Sateesh Apté MD, a board qualified physician trained at Harvard and Stanford. The executive team includes:
Sateesh Apte MD, President, CEO and Founder:
Dr. Apté, in his capacity as managing director of Swiss Pacific Group, Ltd., is the founder of ImmunoScience, Inc. and has served as President and CEO since 1995.
Dr. Apté's interest in a rapid HIV tests in the early 1990's resulted in the development of the Salivax™ test kit. That development process led to further extensive research of HIV / AIDS, resulting in the initial clinical trials for Contre Vir™, the patented HIV therapeutic vaccine that is the catalyst of our organization. Dr. Apté specializes in neurology and has an extensive background in research, teaching and consulting in the field of neurological sciences. The similarities of neurology with the immunology sciences, and his in-depth study in this area, have allowed an easy transport of his medical expertise to the research arena.
His professional appointments have included active staff positions at the VA Medical Center and Valley Memorial Hospital in Livermore, CA; ValleyCare Medical Center in Pleasanton, CA, and directorships with PainCare Medical Clinic, and the Sleep Disorders Center in San Ramon and Pleasanton, CA. He most recently served as President and CEO of Northern California Physicians Associates, Inc. and Alpha Medical Group, Inc. (1986-1992) prior to the inception of ImmunoScience. He has served in numerous professional medical associations and is currently an active member in the American Academy of Neurology and the American Association for the Advancement of Science. His current consulting appointments include The National Multiple Sclerosis Society (1991-present) and the Epilepsy League of America (1991-Present). His undergraduate studies were conducted in Pune, India and his graduate training included residencies at Haffkine Institute, Bombay, India; Boston University Medical Center; Harvard Medical School, Boston, MA; and a senior fellowship at Stanford University Medical Center.
Dr. Apté has authored and co-authored a number of articles for medical publications and has several publications pending. He has been awarded several patents for the therapeutic vaccine, with other patents pending in the US and internationally for the vaccine as well as saliva based diagnostic tests.
Robert Nagy, CPA, CGMA, Chief Financial Officer:
Mr. Nagy is Vice President of Planning and Investor Communications at ImmunoScience, Inc. He has been actively involved with the Company since 1998, helping to pursue and secure capital funding for the company. He has extensive experience in domestic and international tax; merger and acquisition evaluation and planning; capital acquisition and structuring; strategic planning and business analysis, finance, and operations. He has worked with private placements and public offerings, including SEC compliance and reporting. He has been recognized by Money magazine as one of the nation's best tax practitioners. Prior to coming on board full-time with ImmunoScience, Mr. Nagy was President and Managing Director of Meridian Services, Ltd., a boutique public accounting firm providing services in the areas of sophisticated domestic and foreign tax planning and compliance, asset protection strategies, operations and finance. He continues to do some limited work in these areas.
Throughout his 35 plus year career in finance, he has served as CFO, Owner/Managing Director, Senior Manager and Senior Partner of various private and public companies. He is an active member of the American Institute of CPAs and the South Carolina Association of CPAs, and has been a lecturer and seminar leader for continuing professional education courses with both organizations. He has been a board member of numerous civic organizations, is currently serving on the Board of Directors for Charleston Area Senior Citizens Services, Inc., and is active in his church and other civic endeavors. He has been a Certified Public Accountant since 1977. He earned a B.S in Accounting from University of South Carolina and has over 1,200 hours in various tax, accounting, management and SEC courses.
Victor Martin PhD, Vice President, Manufacturing and Regulatory Affairs:
Dr. Martin is Vice President of Manufacturing and Regulatory Affairs of ImmunoScience, Inc., and joined the Company in 1996. Dr. Martin has been critically important in the optimization of the Salivax™ test kits for HIV / AIDS and the development of our other saliva test kits. Prior to coming to ImmunoScience, Dr. Martin worked with BioGenex Laboratories, a biotechnology company making a variety of products and kits for detection systems, Western Blot and cell pathology immunoassays, diagnostic instrumentation, and fine chemicals for DNA/RNA nucleic acid synthesis. He has an extensive background in biotechnology and clinical industries and has broad experience with research and development, as well as quality assurance and product development and optimization. In addition to his work with BioGenex, his experience includes working with the VA Medical Center, Martinez, CA; the Department of Medicine, Department of Nephrology, University of California, Davis; and the Routine Steroid Laboratory at Endocrine Sciences in CA.
Dr. Martin earned his Ph.D. in Chemical Pathology/Clinical Chemistry at St. Bartholomew's Hospital Medical School, University of London, London, UK and a B.Sc. (Honours) in Chemistry at Queen Mary College, University of London, London, UK. His continuing professional studies include the Robert Spivok Associates GMP Seminar, Total Quality Management Studies at University of California, Berkeley and Project Management at University of California, Berkeley.
John Washington, Vice President, Facilities and Human Resources:
Mr. Washington is a Company Vice President in charge of Human Resources and Facilities. John was a very early major investor in ImmunoScience whose participation was key to the clinical trials in Sierra Leone. John had a keen interest is plastic technologies, which he studied at a technical school in Oakland, CA. He was employed by Kaiser Aerospace and then Applied Aerospace, initially as a technician before moving on to research and development responsibilities in the area of plastic composites. Both companies were heavily involved with government contracts for military equipment, communications satellites, military aircraft components and related products. Both companies were innovators in plastic and composite applications.
After spending approximately 15 years in the plastics technology field, John acquired majority ownership of Carlel Cellular Partners. Carlel was an early participant in the cellular phone business. As the principal for this company, John was responsible for both day-to-day operations and strategic growth. Through his efforts, Carlel was sold in the early 90's for close to $20 million. After the sale John temporarily retired. In 1995 he was introduced to ImmunoScience and invested in the Company. Since that time, John has worked as a consultant and as an innovative solver of various technical problems. The most recent was a problem with a separation of the plastic components of the Salivax™ test kit wand. He analyzed the problem, determined a likely fix, and sourced a company that was able to supply a high-pressure, high-frequency bonding machine that solved the problem.
Aniket Apte, CFA, FRM, Vice President, Marketing and Business Development:
Mr. Apte is a Company Vice President in charge of Business Development. Prior to joining ImmunoScience, Inc., Aniket spent five years in the derivatives arbitrage industry with four of those years as a derivatives trader. Hired right out of college by SIG, Aniket, with his knowledge and understanding of both probability and poker theory, was a valuable component to Susquehanna’s trading business. Among the trading issues he faced were index arbitrage, dispersion trading, option pricing in merger situations, and trading during crash situations. In 2007, Aniket worked for PFTC Trading as a Trader and Volatility Analyst where he analyzed statistical relationships between the fundamental data of companies (accounting data, stock trading characteristics) and the future implied volatility of the same companies.
Mr. Apte holds the Chartered Financial Analyst ("CFA") and Financial Risk Manager ("FRM") designations. In December 2006, Aniket was awarded the Wilmott Certificate in Quantitative Finance. Mr. Apte has two bachelor's degrees from the University of California, Berkeley: (Biochemistry and Economics). He received his MBA from the University of Chicago Booth School of Business in 2013.